Insurers cut back GLP-1 coverage as demand soars: Found study
$ 24.50 · 4.6 (198) · In stock
As demand surges for GLP-1 therapies, insurers are pulling back on coverage, according to new data from obesity care provider Found. | Sarah Jones Simmer, CEO of Found, said that the trends are likely the result of irresponsible prescribing for recreational reasons causing the pendulum to swing "all the way in the other direction," and it's leading to patients who have genuine medical need struggling to access these therapies.
Health Plan News Q1 2023
2024 Spring Magellan Rx Report by Magellan Rx Management - Issuu
Global Glucagon-like Peptide 1 (GLP-1) Market Analysis
Why payers are hesitant to cover GLP-1 drugs for weight loss
What Employers Need to Know About Covering GLP-1 Receptor Agonists
/sites/default/files/styles/embed_xxl/p
The official blog of PNHP - PNHP
Glucagon-Like Peptide 1 (GLP-1) Agonists Market to Reach USD 20.15 Billion During Forecast Period - Digital Journal
As the market for new weight loss drugs soars, people with diabetes pay the price
Weight loss drug Wegovy reduces heart disease risk
Why Won't Your Company Pay for Weight-Loss Drugs Like Wegovy